Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Metabolism and pharmacokinetics of naronapride (ATI-7505), a serotonin 5-HT(4) receptor agonist for gastrointestinal motility disorders.

Bowersox SS, Lightning LK, Rao S, Palme M, Ellis D, Coleman R, Davies AM, Kumaraswamy P, Druzgala P.

Drug Metab Dispos. 2011 Jul;39(7):1170-80. doi: 10.1124/dmd.110.037564. Epub 2011 Mar 29.

2.

Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models.

Bowersox SS, Canafax D, Druzgala P, Milner P, Weitz JI.

Thromb Res. 2010 Nov;126(5):e383-8. doi: 10.1016/j.thromres.2010.08.025.

PMID:
20869102
3.

Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.

Choppin A, Irwin I, Lach L, McDonald MG, Rettie AE, Shao L, Becker C, Palme MP, Paliard X, Bowersox S, Dennis DM, Druzgala P.

Br J Pharmacol. 2009 Nov;158(6):1536-47. doi: 10.1111/j.1476-5381.2009.00420.x. Epub 2009 Oct 20.

4.

The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.

Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD.

Circulation. 2009 Sep 22;120(12):1029-35, 2 p following 1035. doi: 10.1161/CIRCULATIONAHA.109.856120. Epub 2009 Sep 8.

5.

Continuous Intrathecal Infusion of Ziconotide for Treatment of Chronic Malignant and Nonmalignant Pain Over 12 Months: A Prospective, Open-label Study.

Ellis DJ, Dissanayake S, McGuire D, Charapata SG, Staats PS, Wallace MS, Grove GW, Vercruysse P; Elan Study 95-002 Group.

Neuromodulation. 2008 Jan;11(1):40-9. doi: 10.1111/j.1525-1403.2007.00141.x.

PMID:
22150990
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk